RAMBALDI ALESSANDRO

Lussana, F., Magnani, C., Galimberti, S., Gritti, G., Gaipa, G., Belotti, D., et al. (2025). Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation. BLOOD CANCER JOURNAL, 15(1) [10.1038/s41408-025-01260-6]. Detail

Castelli, M., Mico, M., Grassi, A., Algarotti, A., Lussana, F., Finazzi, M., et al. (2024). Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience. BONE MARROW TRANSPLANTATION, 59(8), 1161-1168 [10.1038/s41409-024-02305-3]. Detail

Zaninelli, S., Meli, C., Borleri, G., Quaroni, M., Pavoni, C., Gaipa, G., et al. (2024). Optimization and validation of in vivo flow cytometry chimeric antigen receptor T cell detection method using CD19his indirect staining. CYTOMETRY. PART A, 105(2 (February 2024)), 112-123 [10.1002/cyto.a.24796]. Detail

Zaninelli, S., Panna, S., Tettamanti, S., Melita, G., Doni, A., D'Autilia, F., et al. (2024). Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab. ANTIBODIES, 13(3) [10.3390/antib13030071]. Detail

Caserta, C., Nucera, S., Barcella, M., Fazio, G., Naldini, M., Pagani, R., et al. (2023). miR-126 identifies a quiescent and chemo-resistant human B-ALL cell subset that correlates with minimal residual disease. LEUKEMIA, 37(10), 1994-2005 [10.1038/s41375-023-02009-5]. Detail